Enamel matrix derivative
Enamel matrix derivative (EMD) or enamel matrix proteins are proteins that have been found to play a key role in the development of tooth-supporting tissues. For clinical use in regenerative periodontal procedures, they are derived from developing porcine teeth.[1] It was introduced in 1996 and marketed as Emdogain by the Swedish company Biora, until Straumann acquired Biora in 2003 and began producing it under the Straumann name.
Mechanism of action
Enamel matrix derivative, and certainly the amelogenin component, has been suggested to induce formation of acellular cementum and contribute to the regeneration of the periodontal tissues by stimulating proliferation of mesenchymal cells, inhibiting proliferation of epithelial cells and promoting the secretion of certain growth factors, such as TGF-β1, by periodontal ligament cells.
Application of enamel matrix proteins results in a more efficient healing of the periodontal hard tissues with reference to the vertical and horizontal defect resolution in conjunction with open flap debridement than open flap debridement alone.[2]
References
- ^ Hammarström, L; Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997 Sep;24(9 Pt 2):658-68.
- ^ Chitsazi, MT; Farahani, RMZ: Efficacy of open flap debridement with and without enamel matrix derivatives in the treatment of mandibular degree II furcation involvement, Clin Oral Invest July 11, 2007
External links
 | This dentistry article is a stub. You can help Wikipedia by expanding it. |